Eléments de l'association

	Kumaran Deiva	2
	Central Nervous System Diseases (drug therapy)	1
	Kumaran Deiva *Sauf* Central Nervous System Diseases (drug therapy)"	1
	Central Nervous System Diseases (drug therapy) *Sauf* Kumaran Deiva"	0
	Kumaran Deiva Et Central Nervous System Diseases (drug therapy)	1
	Kumaran Deiva Ou Central Nervous System Diseases (drug therapy)	2
	*Corpus*	921

List of bibliographic references

Number of relevant bibliographic references: 1.

Ident.	Authors (with country if any)	Title
000069	Russell C. Dale [Royaume-Uni] ; Fabienne Brilot [Royaume-Uni] ; Lisa V. Duffy [Royaume-Uni] ; Marinka Twilt [Royaume-Uni] ; Amy T. Waldman [Royaume-Uni] ; Sona Narula [Royaume-Uni] ; Eyal Muscal [Royaume-Uni] ; Kumaran Deiva [Royaume-Uni] ; Erik Andersen [Royaume-Uni] ; Michael R. Eyre [Royaume-Uni] ; Despina Eleftheriou [Royaume-Uni] ; Paul A. Brogan [Royaume-Uni] ; Rachel Kneen [Royaume-Uni] ; Gulay Alper [Royaume-Uni] ; Banu Anlar [Royaume-Uni] ; Evangeline Wassmer [Royaume-Uni] ; Kirsten Heineman [Royaume-Uni] ; Cheryl Hemingway [Royaume-Uni] ; Catherine J. Riney [Royaume-Uni] ; Andrew Kornberg [Royaume-Uni] ; Marc Tardieu [Royaume-Uni] ; Amber Stocco [Royaume-Uni] ; Brenda Banwell [Royaume-Uni] ; Mark P. Gorman [Royaume-Uni] ; Susanne M. Benseler [Royaume-Uni] ; Ming Lim [Royaume-Uni]	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease.

Wicri

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021